ARCHIVES

Pfizer’s Withdrawal Of Mylotarg Signals Stronger FDA Resolve To Monitor Confirmatory Studies

This article is from The Cancer Letter archive.

Vol. 36 No. 24 | June 25, 2010

Download PDF Visit The Full Archive

Related Articles

FDA to refer false statements by regulated companies to SEC.

February 27, 2004

In Brief: Diagnostic Imaging Cost Declines By Half as Percentage Of Health Cost In 10 Years

January 11, 1985

Lawyer Says Salick didn’t Anticipate Ouster By Zeneza

May 2, 1997

NIH Authorization Set For Another Try; Women’s Cancers Are Targeted

July 10, 1992

Kennedy Attempts To Establish Unit For All Biomedical Research Similar To Successful Cancer Panel; Administration Threatens Veto

March 15, 1974

Knudson To Head Fox Chase Center

November 21, 1980